These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 10850086)

  • 21. Vitamin D and bone health in postmenopausal women.
    Malabanan AO; Holick MF
    J Womens Health (Larchmt); 2003 Mar; 12(2):151-6. PubMed ID: 12737713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of osteoporosis with active vitamin D3].
    Katagiri H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():392-6. PubMed ID: 15035158
    [No Abstract]   [Full Text] [Related]  

  • 26. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An analysis of calcium pidolate absorption and a comparison with that of a salt in common use, gluconate-lactate-carbonate, in postmenopausal osteoporosis].
    Farrerons J; Olazabal A; Díaz López C; López Ciudad A; Rams A
    An Med Interna; 1989 Jul; 6(7):361-5. PubMed ID: 2491491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percent true calcium absorption, mineral metabolism, and bone mass in children with arthritis: effect of supplementation with vitamin D3 and calcium.
    Hillman LS; Cassidy JT; Chanetsa F; Hewett JE; Higgins BJ; Robertson JD
    Arthritis Rheum; 2008 Oct; 58(10):3255-63. PubMed ID: 18821668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of vitamin D on bone mineral density; bone strength and fracture prevention].
    Okuizumi H; Harada A
    Clin Calcium; 2006 Jul; 16(7):1115-21. PubMed ID: 16816470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
    D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G
    Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of vitamin D dose on bone mineral density.
    Heaney RP
    Osteoporos Int; 2012 Feb; 23(2):789-90; author reply 791. PubMed ID: 22113323
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of patients with postmenopausal osteoporosis].
    Kotova SM; Alesov VZ; Karlova NA; Aleksenko NI; Fedorova AV; Lebedeva NA; Kudriashova GP; Sokhor AIa
    Klin Med (Mosk); 1990 Apr; 68(4):88-92. PubMed ID: 2370790
    [No Abstract]   [Full Text] [Related]  

  • 35. Vitamin D may prevent falls.
    Harv Health Lett; 2010 Jan; 35(3):3. PubMed ID: 20213938
    [No Abstract]   [Full Text] [Related]  

  • 36. High-dose oral vitamin D supplementation and risk of falls in older women.
    Prieto-Alhambra D; Judge A; Pazianas M
    JAMA; 2010 Aug; 304(8):854-5; author reply 856-7. PubMed ID: 20736463
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose oral vitamin D supplementation and risk of falls in older women.
    Malgarini RB; Pimpinella G
    JAMA; 2010 Aug; 304(8):855-6; author reply 856-7. PubMed ID: 20736465
    [No Abstract]   [Full Text] [Related]  

  • 38. Association between vitamin D and falls in young postmenopausal women.
    Palacios S
    Menopause; 2016 Mar; 23(3):239-40. PubMed ID: 26818014
    [No Abstract]   [Full Text] [Related]  

  • 39. Non-pharmacological options may have role in postmenopausal osteoporosis.
    Alonso-Coello P; Marzo-Castillejo M
    BMJ; 2003 Nov; 327(7422):1051. PubMed ID: 14593067
    [No Abstract]   [Full Text] [Related]  

  • 40. Statins and vitamin D.
    Aloia JF; Li-Ng M; Pollack S
    Am J Cardiol; 2007 Oct; 100(8):1329. PubMed ID: 17920383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.